205 related articles for article (PubMed ID: 28438925)
1. Identification of Mycobacterial Genes Involved in Antibiotic Sensitivity: Implications for the Treatment of Tuberculosis with β-Lactam-Containing Regimens.
Viswanathan G; Yadav S; Raghunand TR
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438925
[TBL] [Abstract][Full Text] [Related]
2. Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics.
Cohen KA; El-Hay T; Wyres KL; Weissbrod O; Munsamy V; Yanover C; Aharonov R; Shaham O; Conway TC; Goldschmidt Y; Bishai WR; Pym AS
EBioMedicine; 2016 Jul; 9():170-179. PubMed ID: 27333036
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Multidrug-Resistant Mycobacterium tuberculosis Isolates.
Zhang D; Wang Y; Lu J; Pang Y
Antimicrob Agents Chemother; 2016 Jan; 60(1):393-9. PubMed ID: 26525785
[TBL] [Abstract][Full Text] [Related]
4. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate.
Gonzalo X; Drobniewski F
J Antimicrob Chemother; 2013 Feb; 68(2):366-9. PubMed ID: 23070734
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo efficacy of β-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis.
Solapure S; Dinesh N; Shandil R; Ramachandran V; Sharma S; Bhattacharjee D; Ganguly S; Reddy J; Ahuja V; Panduga V; Parab M; Vishwas KG; Kumar N; Balganesh M; Balasubramanian V
Antimicrob Agents Chemother; 2013 Jun; 57(6):2506-10. PubMed ID: 23507276
[TBL] [Abstract][Full Text] [Related]
6. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K
Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620
[TBL] [Abstract][Full Text] [Related]
7. Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of
Olivença F; Pires D; Silveiro C; Gama B; Holtreman F; Anes E; Catalão MJ
Antimicrob Agents Chemother; 2024 Apr; 68(4):e0158623. PubMed ID: 38411952
[TBL] [Abstract][Full Text] [Related]
8. Genetic analysis of the beta-lactamases of Mycobacterium tuberculosis and Mycobacterium smegmatis and susceptibility to beta-lactam antibiotics.
Flores AR; Parsons LM; Pavelka MS
Microbiology (Reading); 2005 Feb; 151(Pt 2):521-532. PubMed ID: 15699201
[TBL] [Abstract][Full Text] [Related]
9. Can inhibitor-resistant substitutions in the Mycobacterium tuberculosis β-Lactamase BlaC lead to clavulanate resistance?: a biochemical rationale for the use of β-lactam-β-lactamase inhibitor combinations.
Kurz SG; Wolff KA; Hazra S; Bethel CR; Hujer AM; Smith KM; Xu Y; Tremblay LW; Blanchard JS; Nguyen L; Bonomo RA
Antimicrob Agents Chemother; 2013 Dec; 57(12):6085-96. PubMed ID: 24060876
[TBL] [Abstract][Full Text] [Related]
10. The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.
Dinçer I; Ergin A; Kocagöz T
Int J Antimicrob Agents; 2004 Apr; 23(4):408-11. PubMed ID: 15081094
[TBL] [Abstract][Full Text] [Related]
11. [
Shi J; Zheng DW; Ma XG; Su RY; Zhu YK; Wang SH; Chang WJ; Sun GQ; Sun DY
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Aug; 46(8):797-805. PubMed ID: 37536990
[No Abstract] [Full Text] [Related]
12. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis.
Hugonnet JE; Tremblay LW; Boshoff HI; Barry CE; Blanchard JS
Science; 2009 Feb; 323(5918):1215-8. PubMed ID: 19251630
[TBL] [Abstract][Full Text] [Related]
13. Contribution of beta-lactamases to beta-lactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates.
Segura C; Salvadó M; Collado I; Chaves J; Coira A
Antimicrob Agents Chemother; 1998 Jun; 42(6):1524-6. PubMed ID: 9624510
[TBL] [Abstract][Full Text] [Related]
14. [Efficient combination of clavulanate and beta-lactam antibiotics against extensively drug-resistant M. tuberculosis].
Hugonnet JE
Med Sci (Paris); 2009; 25(8-9):661-3. PubMed ID: 19765373
[No Abstract] [Full Text] [Related]
15. Mutation in an Unannotated Protein Confers Carbapenem Resistance in Mycobacterium tuberculosis.
Kumar P; Kaushik A; Bell DT; Chauhan V; Xia F; Stevens RL; Lamichhane G
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069655
[TBL] [Abstract][Full Text] [Related]
16. Structures of
Lu Z; Wang H; Zhang A; Liu X; Zhou W; Yang C; Guddat L; Yang H; Schofield CJ; Rao Z
Mol Pharmacol; 2020 Apr; 97(4):287-294. PubMed ID: 32086254
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial active-site variants confer sustained clavulanate resistance in BlaC β-lactamase from Mycobacterium tuberculosis.
Egesborg P; Carlettini H; Volpato JP; Doucet N
Protein Sci; 2015 Apr; 24(4):534-44. PubMed ID: 25492589
[TBL] [Abstract][Full Text] [Related]
18. Meropenem-clavulanate: a new strategy for the treatment of tuberculosis?
Holzgrabe U
ChemMedChem; 2009 Jul; 4(7):1051-3. PubMed ID: 19462395
[TBL] [Abstract][Full Text] [Related]
19. Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.
Cavanaugh JS; Jou R; Wu MH; Dalton T; Kurbatova E; Ershova J; Cegielski JP;
J Antimicrob Chemother; 2017 Jun; 72(6):1678-1687. PubMed ID: 28333192
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of β-lactam killing and resistance in the context of Mycobacterium tuberculosis.
Wivagg CN; Bhattacharyya RP; Hung DT
J Antibiot (Tokyo); 2014 Sep; 67(9):645-54. PubMed ID: 25052484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
